Research ExplorerPublicationsUpdate Breast Cancer 2022 Part 1 - Early Stage Breast Cancer

Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer

Standard

Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer. / Welslau, Manfred; Müller, Volkmar; Lüftner, Diana; Schütz, Florian; Stickeler, Elmar; Fasching, Peter A; Janni, Wolfgang; Thomssen, Christoph; Witzel, Isabell; Fehm, Tanja N; Belleville, Erik; Bader, Simon; Seitz, Katharina; Untch, Michael; Thill, Marc; Tesch, Hans; Ditsch, Nina; Lux, Michael P; Aktas, Bahriye; Banys-Paluchowski, Maggie; Schneeweiss, Andreas; Harbeck, Nadia; Würstlein, Rachel; Hartkopf, Andreas D; Wöckel, Achim; Seliger, Barbara; Massa, Chiara; Kolberg, Hans-Christian.

In: GEBURTSH FRAUENHEILK, Vol. 82, No. 6, 06.2022, p. 580-589.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Welslau, M, Müller, V, Lüftner, D, Schütz, F, Stickeler, E, Fasching, PA, Janni, W, Thomssen, C, Witzel, I, Fehm, TN, Belleville, E, Bader, S, Seitz, K, Untch, M, Thill, M, Tesch, H, Ditsch, N, Lux, MP, Aktas, B, Banys-Paluchowski, M, Schneeweiss, A, Harbeck, N, Würstlein, R, Hartkopf, AD, Wöckel, A, Seliger, B, Massa, C & Kolberg, H-C 2022, 'Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer', GEBURTSH FRAUENHEILK, vol. 82, no. 6, pp. 580-589. https://doi.org/10.1055/a-1811-6106

APA

Welslau, M., Müller, V., Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Fehm, T. N., Belleville, E., Bader, S., Seitz, K., Untch, M., Thill, M., Tesch, H., Ditsch, N., Lux, M. P., Aktas, B., ... Kolberg, H-C. (2022). Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer. GEBURTSH FRAUENHEILK, 82(6), 580-589. https://doi.org/10.1055/a-1811-6106

Vancouver

Welslau M, Müller V, Lüftner D, Schütz F, Stickeler E, Fasching PA et al. Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer. GEBURTSH FRAUENHEILK. 2022 Jun;82(6):580-589. https://doi.org/10.1055/a-1811-6106

Bibtex

@article{55bba98e2ec84dc69da4cdea47428d90,
title = "Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer",
abstract = "Evidence relating to the treatment of breast cancer patients with early-stage disease has increased significantly in the past year. Abemaciclib, olaparib, and pembrolizumab are new drugs with good efficacy in the relevant patient groups. However, some questions remain unanswered. In particular, it remains unclear which premenopausal patients with hormone receptor-positive breast cancer should be spared unnecessary treatment. The question of the degree to which chemotherapy exerts a direct cytotoxic effect on the tumor or reduces ovarian function through chemotherapy could be of key importance. This group of patients could potentially be spared chemotherapy. New, previously experimental biomarker analysis methods, such as spatial analysis of gene expression (spatial transcriptomics) are gradually finding their way into large randomized phase III trials, such as the NeoTRIP trial. This in turn leads to a better understanding of the predictive factors of new therapies, for example immunotherapy. This review summarizes the scientific innovations from recent congresses such as the San Antonio Breast Cancer Symposium 2021 but also from recent publications.",
author = "Manfred Welslau and Volkmar M{\"u}ller and Diana L{\"u}ftner and Florian Sch{\"u}tz and Elmar Stickeler and Fasching, {Peter A} and Wolfgang Janni and Christoph Thomssen and Isabell Witzel and Fehm, {Tanja N} and Erik Belleville and Simon Bader and Katharina Seitz and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Lux, {Michael P} and Bahriye Aktas and Maggie Banys-Paluchowski and Andreas Schneeweiss and Nadia Harbeck and Rachel W{\"u}rstlein and Hartkopf, {Andreas D} and Achim W{\"o}ckel and Barbara Seliger and Chiara Massa and Hans-Christian Kolberg",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",
year = "2022",
month = jun,
doi = "10.1055/a-1811-6106",
language = "English",
volume = "82",
pages = "580--589",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "6",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Lüftner, Diana

AU - Schütz, Florian

AU - Stickeler, Elmar

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Thomssen, Christoph

AU - Witzel, Isabell

AU - Fehm, Tanja N

AU - Belleville, Erik

AU - Bader, Simon

AU - Seitz, Katharina

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P

AU - Aktas, Bahriye

AU - Banys-Paluchowski, Maggie

AU - Schneeweiss, Andreas

AU - Harbeck, Nadia

AU - Würstlein, Rachel

AU - Hartkopf, Andreas D

AU - Wöckel, Achim

AU - Seliger, Barbara

AU - Massa, Chiara

AU - Kolberg, Hans-Christian

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2022/6

Y1 - 2022/6

N2 - Evidence relating to the treatment of breast cancer patients with early-stage disease has increased significantly in the past year. Abemaciclib, olaparib, and pembrolizumab are new drugs with good efficacy in the relevant patient groups. However, some questions remain unanswered. In particular, it remains unclear which premenopausal patients with hormone receptor-positive breast cancer should be spared unnecessary treatment. The question of the degree to which chemotherapy exerts a direct cytotoxic effect on the tumor or reduces ovarian function through chemotherapy could be of key importance. This group of patients could potentially be spared chemotherapy. New, previously experimental biomarker analysis methods, such as spatial analysis of gene expression (spatial transcriptomics) are gradually finding their way into large randomized phase III trials, such as the NeoTRIP trial. This in turn leads to a better understanding of the predictive factors of new therapies, for example immunotherapy. This review summarizes the scientific innovations from recent congresses such as the San Antonio Breast Cancer Symposium 2021 but also from recent publications.

AB - Evidence relating to the treatment of breast cancer patients with early-stage disease has increased significantly in the past year. Abemaciclib, olaparib, and pembrolizumab are new drugs with good efficacy in the relevant patient groups. However, some questions remain unanswered. In particular, it remains unclear which premenopausal patients with hormone receptor-positive breast cancer should be spared unnecessary treatment. The question of the degree to which chemotherapy exerts a direct cytotoxic effect on the tumor or reduces ovarian function through chemotherapy could be of key importance. This group of patients could potentially be spared chemotherapy. New, previously experimental biomarker analysis methods, such as spatial analysis of gene expression (spatial transcriptomics) are gradually finding their way into large randomized phase III trials, such as the NeoTRIP trial. This in turn leads to a better understanding of the predictive factors of new therapies, for example immunotherapy. This review summarizes the scientific innovations from recent congresses such as the San Antonio Breast Cancer Symposium 2021 but also from recent publications.

U2 - 10.1055/a-1811-6106

DO - 10.1055/a-1811-6106

M3 - SCORING: Review article

C2 - 35903719

VL - 82

SP - 580

EP - 589

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 6

ER -